These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 35890147)

  • 1. Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery.
    Ghanem MS; Caffa I; Del Rio A; Franco J; Parenti MD; Monacelli F; Cea M; Khalifa A; Nahimana A; Duchosal MA; Ravera S; Bertola N; Bruzzone S; Nencioni A; Piacente F
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-Based Identification and Biological Characterization of New NAPRT Inhibitors.
    Franco J; Piacente F; Walter M; Fratta S; Ghanem M; Benzi A; Caffa I; Kurkin AV; Altieri A; Herr P; Martínez-Bailén M; Robina I; Bruzzone S; Nencioni A; Del Rio A
    Pharmaceuticals (Basel); 2022 Jul; 15(7):. PubMed ID: 35890155
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.
    Piacente F; Caffa I; Ravera S; Sociali G; Passalacqua M; Vellone VG; Becherini P; Reverberi D; Monacelli F; Ballestrero A; Odetti P; Cagnetta A; Cea M; Nahimana A; Duchosal M; Bruzzone S; Nencioni A
    Cancer Res; 2017 Jul; 77(14):3857-3869. PubMed ID: 28507103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Versatile Continuous Fluorometric Enzymatic Assay for Targeting Nicotinate Phosphoribosyltransferase.
    Minazzato G; Marangoni E; Fortunato C; Petrelli R; Cappellacci L; Del Bello F; Sorci L; Gasparrini M; Piacente F; Bruzzone S; Raffaelli N
    Molecules; 2023 Jan; 28(3):. PubMed ID: 36770640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NAD Synthesis Pathway Interference Is a Viable Therapeutic Strategy for Chondrosarcoma.
    Peterse EFP; van den Akker BEWM; Niessen B; Oosting J; Suijker J; de Jong Y; Danen EHJ; Cleton-Jansen AM; Bovée JVMG
    Mol Cancer Res; 2017 Dec; 15(12):1714-1721. PubMed ID: 28860121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel NAPRT specific antibody identifies small cell lung cancer and neuronal cancers as promising clinical indications for a NAMPT inhibitor/niacin co-administration strategy.
    Cole J; Guiot MC; Gravel M; Bernier C; Shore GC; Roulston A
    Oncotarget; 2017 Sep; 8(44):77846-77859. PubMed ID: 29100430
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective Cytotoxicity of the NAMPT Inhibitor FK866 Toward Gastric Cancer Cells With Markers of the Epithelial-Mesenchymal Transition, Due to Loss of NAPRT.
    Lee J; Kim H; Lee JE; Shin SJ; Oh S; Kwon G; Kim H; Choi YY; White MA; Paik S; Cheong JH; Kim HS
    Gastroenterology; 2018 Sep; 155(3):799-814.e13. PubMed ID: 29775598
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extensive regulation of nicotinate phosphoribosyltransferase (NAPRT) expression in human tissues and tumors.
    Duarte-Pereira S; Pereira-Castro I; Silva SS; Correia MG; Neto C; da Costa LT; Amorim A; Silva RM
    Oncotarget; 2016 Jan; 7(2):1973-83. PubMed ID: 26675378
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in NAD-Lowering Agents for Cancer Treatment.
    Ghanem MS; Monacelli F; Nencioni A
    Nutrients; 2021 May; 13(5):. PubMed ID: 34068917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAMPT and NAPRT, Key Enzymes in NAD Salvage Synthesis Pathway, Are of Negative Prognostic Value in Colorectal Cancer.
    Li XQ; Lei J; Mao LH; Wang QL; Xu F; Ran T; Zhou ZH; He S
    Front Oncol; 2019; 9():736. PubMed ID: 31448236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights into the NAD
    Pollard CL; Younan A; Swegen A; Gibb Z; Grupen CG
    J Reprod Dev; 2022 Jun; 68(3):216-224. PubMed ID: 35342119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
    Hasmann M; Schemainda I
    Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the NAD Salvage Synthesis Pathway as a Novel Therapeutic Strategy for Osteosarcomas with Low NAPRT Expression.
    Franceschini N; Oosting J; Tamsma M; Niessen B; Bruijn IB; van den Akker B; Kruisselbrink AB; Palubeckaitė I; Bovée JVMG; Cleton-Jansen AM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34200964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NAPRT, but Not NAMPT, Provides Additional Support for NAD Synthesis in Esophageal Precancerous Lesions.
    Wang N; Pan D; Wang X; Su M; Wang X; Yan Q; Sun G; Wang S
    Nutrients; 2022 Nov; 14(22):. PubMed ID: 36432602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression patterns of nicotinamide phosphoribosyltransferase and nicotinic acid phosphoribosyltransferase in human malignant lymphomas.
    Olesen UH; Hastrup N; Sehested M
    APMIS; 2011 Apr; 119(4-5):296-303. PubMed ID: 21492230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NAD pool as an antitumor target against cancer stem cells in head and neck cancer.
    Navas LE; Blanco-Alcaina E; Suarez-Martinez E; Verdugo-Sivianes EM; Espinosa-Sanchez A; Sanchez-Diaz L; Dominguez-Medina E; Fernandez-Rozadilla C; Carracedo A; Wu LE; Carnero A
    J Exp Clin Cancer Res; 2023 Mar; 42(1):55. PubMed ID: 36864434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevation of cellular NAD levels by nicotinic acid and involvement of nicotinic acid phosphoribosyltransferase in human cells.
    Hara N; Yamada K; Shibata T; Osago H; Hashimoto T; Tsuchiya M
    J Biol Chem; 2007 Aug; 282(34):24574-82. PubMed ID: 17604275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAD Metabolism in Cancer Therapeutics.
    Yaku K; Okabe K; Hikosaka K; Nakagawa T
    Front Oncol; 2018; 8():622. PubMed ID: 30631755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NAMPT and NAPRT serum levels predict response to anti-TNF therapy in inflammatory bowel disease.
    Colombo G; Caviglia GP; Ravera A; Tribocco E; Frara S; Rosso C; Travelli C; Genazzani AA; Ribaldone DG
    Front Med (Lausanne); 2023; 10():1116862. PubMed ID: 36817780
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Duarte-Pereira S; Fajarda O; Matos S; Luís Oliveira J; Silva RM
    Genes (Basel); 2021 Dec; 12(12):. PubMed ID: 34946971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.